FIELD: medicine.
SUBSTANCE: invention is intended for prevention of fetoplacental insufficiency (FPI) for pregnant women with chronic kidney disease (CKD). An antiaggregant is prescribed at a preventive dose. In addition, pregnant women with pathology interstitial at CKD of stages III-V, glomerulopathies at CKD receive heparin therapy at a preventive dose. For pregnant women with stage II CKD, plasma hemostasis is examined by thrombodynamics and if at least two spontaneous clots are detected during 30 minutes of observation, heparin therapy is carried out at a preventive dose. Further, the state of the plasma hemostasis is monitored by thrombodynamics at least once every 20 days. If at least two spontaneous clots are detected within 30 minutes of observation, the preventive dose of heparin is adjusted upwards.
EFFECT: method allows to provide prevention of fetoplacental insufficiency.
3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREECLAMPSIA DIAGNOSTICS IN PREGNANT WOMEN WITH CHRONIC KIDNEY DISEASE | 2016 |
|
RU2623057C1 |
METHOD FOR CORRECTION OF HAEMOSTASIS DISORDERS IN FEMALES ACCOMPANYING EXTRACORPOREAL FERTILIZATION | 2018 |
|
RU2723358C2 |
METHOD FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN POST-OPERATIVE PERIOD OF PATIENTS WITH MORBIDITY OBESITY AFTER LAPAROSCOPIC HYSTERECTOMY | 2017 |
|
RU2650975C1 |
METHOD OF TREATING PREGNANT WOMEN WITH CHRONIC KIDNEY DISEASE | 2023 |
|
RU2819989C1 |
METHOD OF PREVENTING GESTATIONAL COMPLICATIONS IN PREGNANT WOMEN WITH EPILEPSY | 2017 |
|
RU2657772C1 |
METHOD FOR PREDICTING ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH TYPE 1 DIABETES MELLITUS IN THE SECOND HALF OF PREGNANCY | 2020 |
|
RU2759076C1 |
METHOD OF TREATING ACUTE VENOUS THROMBOSES OF VARIOUS LOCALISATIONS WITH UNDERLYING HEMORRHAGIC COMPLICATIONS | 2012 |
|
RU2477636C1 |
METHOD FOR PREVENTING THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH MULTIPLE FRACTURES OF LIMB LONG BONES | 2019 |
|
RU2726358C1 |
METHOD FOR DETERMINING THE DURATION OF THROMBOPROPHYLAXIS WITH LOW-MOLECULAR-WEIGHT HEPARIN AFTER ABDOMINAL DELIVERY IN CARRIERS OF THE LEIDEN MUTATION, GENOTYPE F5 G1691A | 2020 |
|
RU2752776C1 |
DRUG AND METHOD OF CORRECTION OF HEMOSTASIS INDICES IN INCOMPLETE PREGNANCY | 1996 |
|
RU2146527C1 |
Authors
Dates
2017-06-21—Published
2016-07-19—Filed